US antivirals major Gilead Sciences (Nasdaq: GILD) yesterday released positive top-line results from the Phase III ASCENT-03 ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences (GILD) stock in focus as cancer drug Trodelvy outperforms chemotherapy in a Phase 3 trial for advanced triple ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

Gilead Sciences is a dominant player in the HIV market with market-leading treatments. HIV drug sales accounted for 69% of ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

RedDrop, a rising star in the wellness industry for its innovative tween period care and education, today drops its newest ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual ...